(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
One dead, six wounded in various crime-related shootings in Israel over the weekend - 2State asks High Court to reject challenge to anti-UNRWA laws ahead of Monday hearing
- 3'The Drama' plot twist, explained: What did Zendaya's character do, and what happens to her wedding?
- 4'Outrageous and illegal' : UNRWA slams Israel for cutting off its water, comms and electric in Gaza
- 56 Famous Urban communities for Shopping on the planet
- Instructions to Decide the Best SUV Size for Seniors
- Ukraine: Russians abduct 50 Ukrainians from border village in Sumy
- 19 Strange Motion pictures You Shouldn't Watch With Your Mum
- Major railway disruptions persist as Germany braces for more snow
- Africa's energy giants eye long-term gains on Iran war disruption
- With Obamacare premium hikes, more people opting for no coverage or cheaper plans
- Scientists find evidence that an asteroid contains tryptophan
- Coffee Prices Finish Higher on Brazil Cop Concerns
- Gartex Texprocess India to showcase innovations across textile ecosystem
